



THE  
BLADDER CANCER  
COMPANY

## Photocure ASA: Transactions made under share buyback program

Oslo, Norway, 13 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets.

For the period from and including 19 December 2024, through 10 January 2025, the Company purchased a total of 258,670 shares at an average price of NOK 60.97 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

Date	Aggregated daily volume (#shares)	Weighted average share price per day (NOK)	Total daily transaction value (NOK)
06.01.2025	20 758	59.13	1,227,414
07.01.2025	20,114	59.01	1,186,850
08.01.2025	22,725	58.93	1,339,138
09.01.2025	21,658	58.92	1,276,188
10.01.2025	22,613	58.72	1,327,907
Previously disclosed buybacks under the program (accumulated)	150,802	62.43	9,414,253
Accumulated under the program	258,670	60.97	15,771,753

### The issuer's holding of own shares:

Following the completion of the above transactions, Photocure owns a total of 273,792 of own shares (including 15,122 shares owned prior to the launch of the buyback program), corresponding to 1.01% of Photocure's share capital.

### Appendix:

An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at [www.newsweb.no](http://www.newsweb.no).

For further information, please contact:

Erik Dahl  
CFO

Photocure ASA  
Tel: +4745055000  
Email: ed@photocure.com

### **About Photocure ASA**

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at [www.photocure.com](http://www.photocure.com) and [www.cysview.com](http://www.cysview.com). All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.